KeyBioscience Announces Extension Of Strategic Collaboration With Lilly On DACRA With An Additional Collaboration Molecule And Investigation Of The DACRA Platform Within Multiple Indications
Portfolio Pulse from Benzinga Newsdesk
KeyBioscience and Eli Lilly have extended their collaboration on DACRA, a new class of treatments for obesity and related disorders. The agreement includes a new molecule entering Phase 2 trials, with Lilly gaining worldwide rights to develop and commercialize DACRA molecules. KeyBioscience will receive up to $1.4B in milestone payments and royalties.
October 10, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly extends its collaboration with KeyBioscience on DACRA, gaining worldwide rights to develop and commercialize these molecules. This could enhance Lilly's portfolio in obesity treatments, potentially leading to significant revenue from milestone payments and royalties.
The extension of the collaboration with KeyBioscience allows Lilly to expand its portfolio in obesity treatments, a significant market. The potential for milestone payments and royalties indicates a positive financial impact. The new molecule entering Phase 2 trials suggests progress in development, which is likely to be viewed favorably by investors.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90